Inhibrx Biosciences (INBX) - Long-Term Liabilities to Capital

Inhibrx Biosciences (INBX) develops protein-based oncology drugs, leveraging partnerships with pharmaceutical behemoths and the acquisition of antibody platforms. Funding relies on grants and external investments due to the absence of commercial products, with the indicator standing at 0.00. The dynamics of the company's debt obligations and equity are reflected in the market price shown on this chart.

For the biotech startup Inhibrx Biosciences (INBX), which relies on external financing for the development of oncology drugs, the long-term debt-to-equity trend serves as an indicator of financial stability. This ratio compares liabilities with maturities exceeding one year against net asset value, allowing for an assessment of the credit load and the risk of liquidity shortages before the company achieves stable revenue.